428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rilvegostomig Triple-Negative Breast Carcinoma	AstraZeneca	P2	CCC (55)
Sarilumab Triple-Negative Breast Carcinoma	University of Southern California	P2	CCC (55)
Trastuzumab Duocarmazine Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (55)
Trastuzumab Emtansine Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (55)
Tucatinib Triple-Negative Breast Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (55)
Zanidatamab Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (55)
Fludarabine Triple-Negative Breast Carcinoma	Canadian Cancer Trials Group	P2	CCC (54)
Selinexor Triple-Negative Breast Carcinoma	National University Hospital, Singapore	P1/2	CCC (54)
Spartalizumab Triple-Negative Breast Carcinoma	SOLTI Breast Cancer Research Group	P2	CCC (54)
Vistusertib Triple-Negative Breast Carcinoma	Queen Mary University of London	P1/2	CCC (54)
Adebrelimab Triple-Negative Breast Carcinoma	Henan Cancer Hospital	P2	CCC (53)
ak131 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Anakinra Triple-Negative Breast Carcinoma	University Health Network, Toronto	P2	CCC (53)
Apsolol Triple-Negative Breast Carcinoma	Emory University	P2	CCC (53)
Atropine Triple-Negative Breast Carcinoma	MedSIR	P2	CCC (53)
b1: trop2 adc Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
bp102 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
c105 Triple-Negative Breast Carcinoma	University of Washington	P2	CCC (53)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine Triple-Negative Breast Carcinoma	University of Washington	P2	CCC (53)
Ceralasertib Triple-Negative Breast Carcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P2	CCC (53)
Chiauranib Triple-Negative Breast Carcinoma	Chipscreen Biosciences, Ltd.	P2	CCC (53)
Cromoglicic Acid Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Disitamab Vedotin Triple-Negative Breast Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Efavirenz Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
hb0025 Triple-Negative Breast Carcinoma	Huabo Biopharm Co., Ltd.	P2	CCC (53)
hb1801 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
HER3 Dendritic Cell Vaccine Triple-Negative Breast Carcinoma	Roswell Park Cancer Institute	P2	CCC (53)
hlx43 Triple-Negative Breast Carcinoma	Shanghai Henlius Biotech	P2	CCC (53)
Hrs-4508 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Hrs-6209 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-2304 -(Ighd) -Ighj401, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg103 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 -Igkj101, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Triple-Negative Breast Carcinoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P2	CCC (53)
ibi354 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
int230-6 Triple-Negative Breast Carcinoma	Swiss Cancer Institute	P2	CCC (53)
Ivuxolimab Triple-Negative Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (53)
js207 Triple-Negative Breast Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (53)
Jskn003 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Ligufalimab Triple-Negative Breast Carcinoma	Akeso	P2	CCC (53)
Mecapegfilgrastim Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Mitoxantrone Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Pelareorep Triple-Negative Breast Carcinoma	Mridula George, MD	P2	CCC (53)
Penpulimab Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Poly((N-(2-Hydroxypropyl)Methacrylamide)-Co-(Methacryloyl-Gly-Phe-Leu-Gly Amide With O-((Trans-4-Aminocyclohexyl)Carbamoyl)Fumagillol)) (~0.91:0.09 X) Triple-Negative Breast Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
qlc5513 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Risedronic Acid Triple-Negative Breast Carcinoma	Harbin Medical University	P2	CCC (53)
Shr-4602 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Shr-A1921 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Sry-Box Transcription Factor 2 Triple-Negative Breast Carcinoma	University of Washington	P2	CCC (53)
Tamoxifen Triple-Negative Breast Carcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Theophylline Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
tj107 Triple-Negative Breast Carcinoma	TJ Biopharma Co., Ltd.	P2	CCC (53)

Showing 101 to 150 of 428 assets

PreviousPage 3 of 9Next